Avalo Therapeutics (AVTX) Earnings Date
The next earnings date for Avalo Therapeutics (AVTX) is around Jan 11, 2027, estimated from its own calendar.
- Next earnings date
- Around Jan 11, 2027
- estimated from its own calendar · quarter ending Dec '26
- Latest stored quarter
- EPS −0.34
- revenue $0.00 · reported Nov 5, 2026
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
1 of 1 scored quarter beat, yet the stock still fell after 1 of them (Nov 5, 2026).
| Report | Est EPS | Act EPS | Surprise | Est rev | Act rev | Reaction |
|---|---|---|---|---|---|---|
| Nov 5, 20268-K, before open · 7:00 am ET | −0.59 | −0.34 | +42.2% | $0.00 | $0.00 | −6.2%release day |
| Aug 6, 20268-K, before open · 7:01 am ET | −0.58adjusted basis | −0.83 | —a Withheld: the reported earnings per share fall well short of the estimate while revenue does not, the usual sign of an adjusted estimate set against reported earnings. | $0.00 | $0.00 | −0.7%release day |
| May 13, 20268-K, before open · 7:00 am ET | — | −0.98 | — | — | $0.00 | −0.5%release day |
| Jan 12, 20268-K, before open · 7:53 am ET | — | −1.02 | — | — | $59,000.00 | −1.7%release day |
| Nov 6, 20258-K, before open · 7:02 am ET | — | −2.19 | — | — | $0.00 | −6.3%release day |
| Aug 7, 20258-K, before open · 7:02 am ET | — | −1.92 | — | — | $0.00 | +0.5%release day |
| May 12, 20258-K, before open · 7:01 am ET | — | −1.25 | — | — | $0.00 | −1.5%release day |
| Mar 20, 20258-K, before open · 7:02 am ET | — | −7.98 | — | — | $192,000.00 | +2.9%release day |
- a Withheld: the reported earnings per share fall well short of the estimate while revenue does not, the usual sign of an adjusted estimate set against reported earnings.
1 of the 8 quarters above is scored against the consensus we stored the night before each report; we began storing it in Jul 2026. 6 reported before we stored a consensus for them, so they are not scored. 1 is not scored for the reason marked beside it. We never backfill an estimate we didn't observe.
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 7 | 3 | 8 | 9 |
| Avg estimate | −0.45 | −0.51 | −2.42 | −2.36 |
| Low estimate | −0.52 | −0.56 | −2.71 | −2.89 |
| High estimate | −0.35 | −0.43 | −2.22 | −1.50 |
| Year-ago EPS | −1.02 | −0.98 | −5.84 | −2.42E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 0 | 0 | 12 | 12 |
| Avg estimate | $0.00 | $0.00 | $1.0M | $1.0M |
| Low estimate | $0.00 | $0.00 | $1.0M | $1.0M |
| High estimate | $0.00 | $0.00 | $1.0M | $1.0M |
| Year-ago revenue | $59,000.00 | $0.00 | $59,000.00 | $1.0ME |
| Implied growth | −100.0% | — | +1594.9% | 0.0% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −0.45 | −0.51 | −2.42 | −2.36 |
| 7 days ago | −0.46 | — | −2.50 | −2.45 |
| 30 days ago | −0.55 | — | −2.92 | −2.98 |
| 60 days ago | −0.55 | — | −2.86 | −2.98 |
| 90 days ago | −0.52 | — | −2.86 | −2.88 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved −$0.52 → −$0.45 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
When does Avalo Therapeutics report earnings next?
Avalo Therapeutics' next earnings date is around Jan 11, 2027, estimated from its own calendar.
What were Avalo Therapeutics' latest quarterly earnings?
Avalo Therapeutics reported diluted EPS of −0.34 and revenue of $0.00 on Nov 5, 2026.
How did Avalo Therapeutics' stock move after its last earnings report?
Avalo Therapeutics moved −6.2% in the session after its Nov 5, 2026 report.

